Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , May 20, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed
View HTML
Toggle Summary Biocept Reports First Quarter 2019 Financial Results
- Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened pathology partnership service - Conference call begins at 4:30 p.m.
View HTML
Toggle Summary Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
SAN DIEGO , May 1, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnosed with cancer, announces
View HTML
Toggle Summary Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized to deliver on key initiatives in 2019 including growth from pathology partnership and
View HTML
Toggle Summary Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment
Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO , March 26, 2019 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019
SAN DIEGO , March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device
Biocept expands intellectual property position to 32 issued patents globally for its highly sensitive methods for detecting cancer biomarkers in blood and other specimen types SAN DIEGO , March 18, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
View HTML
Toggle Summary Biocept Announces Pricing of $8.2 Million Registered Direct Offering
SAN DIEGO , March 15, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
View HTML
Toggle Summary Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services
Proprietary platform enables local pathologists to participate in liquid biopsy testing with new capabilities to evaluate circulating tumor cells (CTCs) and expanded menu of biomarkers SAN DIEGO , March 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid
View HTML
Toggle Summary Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting
Analytical validation of liquid biopsy test for ESR1 mutations offers potential clinical utility by identifying biomarkers that may drive acquired resistance to hormone therapy in breast cancer SAN DIEGO , March 4, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
View HTML